Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | IDE | P14735 | 1/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | DDO | Q99489 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GPR3 | P46089 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887071 | 0.79 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTIDEMPI | |
| SCHEMBL577953 | 0.78 | NPC1 (0.52) | ALDH1A1KDM4EMAPTIDEMPI | |
| SCHEMBL30014118 | 0.78 | NPC1 (0.52) | ALDH1A1KDM4EMAPTIDEMPI | |
| SCHEMBL1590490 | 0.76 | ALDH1A1 (0.61) | ALDH1A1KDM4EGAAHPGDLMNA | |
| SCHEMBL103993 | 0.76 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTGAAHPGD | |
| SCHEMBL3253183 | 0.76 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTIDEMPI | |
| SCHEMBL14247484 | 0.76 | KDM4E (0.50) | ALDH1A1KDM4EMAPTIDEMPI | |
| SCHEMBL30558024 | 0.76 | KDM4E (0.50) | ALDH1A1KDM4EMAPTIDEMPI | |
| SCHEMBL11214071 | 0.76 | PDE10A (0.44) | ALDH1A1KDM4EMAPTIDEMPI | |
| SCHEMBL3111166 | 0.75 | KDM4E (0.59) | ALDH1A1KDM4EMAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-7595402-B2 | Prodrugs of selective androgen receptor modulators and methods of use thereof | GTX, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595402-B2 | Prodrugs of selective androgen receptor modulators and methods of use thereof | GTX, INC. (US) | 2009-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | ALDH1A1 217/4885KDM4E 221/4885MAPT 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.